137 related articles for article (PubMed ID: 12063557)
1. Reduced response of prostate cancer cells to TRAIL is modulated by NFkappaB-mediated inhibition of caspases and Bid activation.
Eid MA; Lewis RW; Abdel-Mageed AB; Kumar MV
Int J Oncol; 2002 Jul; 21(1):111-7. PubMed ID: 12063557
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
3. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
4. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
6. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
Voelkel-Johnson C; King DL; Norris JS
Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
[TBL] [Abstract][Full Text] [Related]
7. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
8. Mitochondria from TRAIL-resistant prostate cancer cells are capable of responding to apoptotic stimuli.
Liang Y; Eid MA; Lewis RW; Kumar MV
Cell Signal; 2005 Feb; 17(2):243-51. PubMed ID: 15494215
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells.
Yu R; Mandlekar S; Ruben S; Ni J; Kong AN
Cancer Res; 2000 May; 60(9):2384-9. PubMed ID: 10811114
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
13. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
14. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
Tong X; Li H
Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
[TBL] [Abstract][Full Text] [Related]
15. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE
Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells.
Nesterov A; Ivashchenko Y; Kraft AS
Oncogene; 2002 Feb; 21(7):1135-40. PubMed ID: 11850832
[TBL] [Abstract][Full Text] [Related]
17. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
Shankar S; Singh TR; Srivastava RK
Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
[TBL] [Abstract][Full Text] [Related]
18. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis.
Yamaguchi K; Uzzo RG; Pimkina J; Makhov P; Golovine K; Crispen P; Kolenko VM
Oncogene; 2005 Sep; 24(38):5868-77. PubMed ID: 15897871
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
[TBL] [Abstract][Full Text] [Related]
20. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
Aggarwal BB; Bhardwaj U; Takada Y
Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]